NCT06991114 Phase 2
Recruiting
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Enrollment
90 pts
Location
United States, Bulga...
Sponsor
Artiva Biotherapeutics, Inc.
NCT07374107
Recruiting
MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
Enrollment
700 pts
Location
United States
Sponsor
Myositis International Health ...